Literature DB >> 18344724

Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder.

Frédérique Van den Eynde1, Vesile Senturk, Kris Naudts, Caroline Vogels, Katrien Bernagie, Olivier Thas, Cornelis van Heeringen, Kurt Audenaert.   

Abstract

Data on the efficacy of quetiapine in borderline personality disorder (BPD) are still scarce. We aimed to investigate the efficacy of quetiapine for impulsivity and a broad range of affective symptoms in BPD. In this 12-week open-label study, we included individuals with BPD who presented to psychiatric in- and outpatient services. After a gradual titration of quetiapine, a flexible dose (range, 100-800 mg) was administered. The main outcome measures consisted of the scores on patient-rated questionnaires (Barratt Impulsiveness Scale, Buss-Durkee Hostility Inventory, Affective Lability Scale, Spielberger State and Trait Anxiety Inventory, Spielberger State and Trait Anger Inventory, and Beck Depression Inventory) and on neurocognitive tasks related to impulsivity (Stroop Color Word Task and IOWA Gambling Task). A mixed linear model, correcting for age, sex, antidepressant use, and weeks in psychotherapy, was applied. Forty-one patients (34 females and 7 males; mean [SD] age, 27.0 [9.0] years) were enrolled in the study, 32 of which completed the trial. Patients' scores decreased significantly (mean [SD] difference; P value) on the Barratt Impulsiveness Scale (19.7 [2.0]; P < 0.0001), Buss-Durkee Hostility Inventory (11.5 [1.4]; P < 0.0001), Affective Lability Scale (0.75 [0.08]; P < 0.0001), Beck Depression Inventory (25.0 [1.7]; P < 0.0001), Spielberger State and Trait Anxiety Inventory state (19.9 [1.9]; P < 0.0001) and trait (20.8 [1.7]; P < 0.0001) subscale, and Spielberger State and Trait Anger Inventory state (7.3 [1.1]; P < 0.0001) and trait (10.1 [1.0]; P < 0.0001) subscale. In addition, patients showed significantly less inference on the Stroop Color Word Task and had more 'good choices' on the IOWA Gambling Task. These results suggest that quetiapine may be efficacious in the treatment of impulsivity and affective symptoms in BPD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344724     DOI: 10.1097/JCP.0b013e318166c4bf

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  17 in total

Review 1.  State of the art in the pharmacologic treatment of borderline personality disorder.

Authors:  Louis Feurino; Kenneth R Silk
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

Review 2.  Pharmacotherapy for borderline personality disorder--current evidence and recent trends.

Authors:  Jutta M Stoffers; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

3.  Impaired decision making in adolescent suicide attempters.

Authors:  Jeffrey A Bridge; Sandra M McBee-Strayer; Elizabeth A Cannon; Arielle H Sheftall; Brady Reynolds; John V Campo; Kathleen A Pajer; Rémy P Barbe; David A Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-02-22       Impact factor: 8.829

4.  A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving.

Authors:  Lara A Ray; Pauline F Chin; Andia Heydari; Karen Miotto
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

5.  Quetiapine improves response inhibition in alcohol dependent patients: a placebo-controlled pilot study.

Authors:  Nathasha Moallem; Lara A Ray
Journal:  Pharmacol Biochem Behav       Date:  2011-10-20       Impact factor: 3.533

Review 6.  Aggression in borderline personality disorder.

Authors:  K Látalová; J Prasko
Journal:  Psychiatr Q       Date:  2010-09

7.  Epigenetics in Developmental Disorder: ADHD and Endophenotypes.

Authors:  Trevor Archer; Marlene Oscar-Berman; Kenneth Blum
Journal:  J Genet Syndr Gene Ther       Date:  2011-06-30

Review 8.  Impulsivity in borderline personality disorder: a matter of disturbed impulse control or a facet of emotional dysregulation?

Authors:  Alexandra Sebastian; Gitta Jacob; Klaus Lieb; Oliver Tüscher
Journal:  Curr Psychiatry Rep       Date:  2013-02       Impact factor: 5.285

9.  Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability.

Authors:  Silvio Bellino; Paola Bozzatello; Camilla Rinaldi; Filippo Bogetto
Journal:  Depress Res Treat       Date:  2011-08-04

10.  Psychopharmacologic treatment of borderline personality disorder.

Authors:  Luis H Ripoll
Journal:  Dialogues Clin Neurosci       Date:  2013-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.